Prognostic Value of Combining Apelin-12 and Estimated Glomerular Filtration Rate in Patients with ST-Segment...

Area of Science:

• Cardiology
• Biomarker Research
• Renal Function Assessment

Background:

• Apelin-12 and estimated glomerular filtration rate (eGFR) are known prognostic factors for ST-segment elevation myocardial infarction (STEMI).
• The combined prognostic value of apelin-12 and eGFR in STEMI patients remains largely unexplored.
• This study investigates the synergistic effect of these biomarkers on STEMI prognosis.

Purpose of the Study:

• To evaluate the enhanced prognostic value of combining apelin-12 and eGFR in patients with STEMI.
• To determine if the combined assessment of apelin-12 and eGFR offers superior prediction of major adverse cardiac events (MACE) compared to individual markers.
• To identify optimal cut-off values for apelin-12 and eGFR in predicting STEMI outcomes.

Main Methods:

• A cohort of 460 STEMI patients was analyzed.
• Patients were stratified into four groups based on median apelin-12 and eGFR levels.
• Cox regression, Kaplan-Meier analysis, and ROC curves were employed to assess prognostic factors and predictive values.

Main Results:

• Major adverse cardiac events (MACE) occurred in 25.7% of patients over 30 months.
• The combined apelin-12 and eGFR assessment demonstrated enhanced predictive value for MACE (AUC, 0.699) compared to apelin-12 (AUC, 0.617) or eGFR (AUC, 0.596) alone.
• A negative correlation was observed between apelin-12 and eGFR (r = -0.32, p < 0.001).

Conclusions:

• Low apelin-12 (<0.76 ng/ml) and low eGFR (<94.06 mL/min/1.73 m²) are independently associated with poor prognosis in STEMI.
• The combination of apelin-12 and eGFR significantly enhances prognostic value in STEMI patients.
• This combined biomarker approach offers a more robust tool for risk stratification in STEMI.